iShares US Healthcare Providers ETFIHF
IHF
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
10,040% more call options, than puts
Call options by funds: $507K | Put options by funds: $5K
0.77% less ownership
Funds ownership: 40.55% [Q4 2024] → 39.78% (-0.77%) [Q1 2025]
4% less funds holding
Funds holding: 196 [Q4 2024] → 189 (-7) [Q1 2025]
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
31% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 59
74% less capital invested
Capital invested by funds: $1.08B [Q4 2024] → $277M (-$803M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for IHF.
Financial journalist opinion
Negative
Seeking Alpha
1 week ago
IHF: Clouds Linger Over Healthcare Providers
iShares U.S. Healthcare Providers ETF faces operational uncertainty and poor momentum, due to sector headwinds and UNH's troubles, justifying my hold rating. Valuation is attractive with a low P/E and PEG ratio, but significant bad news is already priced in, limiting downside conviction. Portfolio concentration in top holdings and low dividend yield make IHF risky and unattractive for income-focused investors.
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
Designed to provide broad exposure to the Healthcare - Healthcare - Providers segment of the equity market, the iShares U.S. Healthcare Providers ETF (IHF) is a passively managed exchange traded fund launched on 05/01/2006.
Neutral
Zacks Investment Research
2 months ago
6 ETFs Showing Great Resilience Amid Market Sell-Offs
U.S. stocks have been witnessing massive sell-offs this month due to trade tensions. However, these ETFs survived the bloodbath.
Neutral
Zacks Investment Research
2 months ago
Diagnosing the Market on Health Day: 6 ETFs Looking Healthy
Following the worst week since the start of the pandemic, let's examine the health of the U.S. stock market on World Health Day.
Negative
Zacks Investment Research
2 months ago
5 ETFs Withstanding the Biggest Market Drop Since 2020
The major U.S. indices log their biggest one-day slide in five years. Here are five ETFs that succeeded in withstanding the turmoil.
Neutral
Seeking Alpha
2 months ago
IHF: Healthcare Dashboard For March
This article provides a top-down analysis of the healthcare sector, using key industry metrics. The healthcare equipment industry offers the best combination of value and quality scores, whereas pharmaceuticals/biotechnology is the most overvalued subsector. iShares U.S. Healthcare Providers ETF is highly concentrated and has underperformed the sector benchmark XLV since 2006, making it less appealing for long-term investment.
Neutral
Seeking Alpha
3 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
Zacks Investment Research
4 months ago
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
If you're interested in broad exposure to the Healthcare - Healthcare - Providers segment of the equity market, look no further than the iShares U.S. Healthcare Providers ETF (IHF), a passively managed exchange traded fund launched on 05/01/2006.
Neutral
Seeking Alpha
5 months ago
IHF: Healthcare Dashboard For December
This article provides a top-down analysis of the healthcare sector, focusing on fundamental and momentum metrics. Healthcare providers are reasonably valued, while other subsectors are overvalued by 9% to 21%, with pharmaceuticals/biotechnology being the least appealing. iShares U.S. Healthcare Providers ETF: valuation may be OK, but beware concentration and volatility.
Charts implemented using Lightweight Charts™